Annual report pursuant to Section 13 and 15(d)

Collaborative, Licensing and Other Arrangements - Novartis - Additional Information (Details)

v3.8.0.1
Collaborative, Licensing and Other Arrangements - Novartis - Additional Information (Details)
$ / shares in Units, € in Millions
3 Months Ended 12 Months Ended
Aug. 24, 2017
USD ($)
$ / shares
shares
Aug. 24, 2017
EUR (€)
shares
Sep. 30, 2017
USD ($)
Jun. 30, 2017
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2017
USD ($)
Dec. 31, 2015
USD ($)
Novartis Pharma AG [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Common stock aggregate fair value $ 4,800,000            
Common stock premium 200,000            
Novartis Pharma AG [Member] | Common Stock [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Cash received from sale of shares $ 5,000,000            
Number of shares sold | shares 539,131 539,131          
Sale of stock price per share | $ / shares $ 9.2742            
Common stock closing price | $ / shares $ 8.93            
Novartis Pharma AG [Member] | Les Laboratories Servier [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Repayments of debt $ 14,300,000 € 12.0          
Novartis Pharma AG [Member] | XOMA-052 License Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
License agreement consideration received 30,000,000            
Upfront payment received 15,700,000            
Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones 438,000,000            
Revenue recognized under licensing agreement           $ 0  
Milestone received under license agreement           0  
Novartis Pharma AG [Member] | IL-1 Target License Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Upfront payment received 10,000,000            
Novartis Pharma AG [Member] | XOMA-052 License Agreement and IL-1 Target License Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
License agreement consideration received 40,200,000            
Upfront payment received 25,700,000            
Common stock premium 200,000            
Novartis Pharma AG [Member] | XOMA-052 License Agreement and IL-1 Target License Agreement [Member] | Les Laboratories Servier [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Repayments of debt 14,300,000            
Novartis Pharma AG [Member] | IL-1 Beta IP License Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Revenue recognized under licensing agreement           31,900,000  
Novartis Pharma AG [Member] | Gevokizumab License Agreement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Revenue recognized under licensing agreement           8,300,000  
Novartis International [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Cash received from sale of shares $ 5,000,000            
Number of shares sold | shares 539,131 539,131          
Common stock aggregate fair value $ 4,800,000            
Common stock closing price | $ / shares $ 8.93            
Common stock premium $ 200,000            
Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones           470,000,000  
Revenue recognized under licensing agreement     $ 35,400,000        
Performance deliverable period for license and regulatory services             90 days
Performance deliverable period for transfer of materials, process and knowhow             90 days
Performance deliverables value on stand alone basis             $ 0
Novartis International [Member] | Collaborative Arrangement [Member]              
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]              
Upfront payment received         $ 37,000,000    
Eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones           480,000,000  
Milestone received under the collaboration agreement       $ 10,000,000   $ 10,000,000